ISDS Case Map
medicines
Drugmakers and healthcare activists are worried that the India-European Union Free Trade Agreement (FTA), which is in the works, may contain a provision that could imperil local industry and have urged the government to keep patent infringement issues out of FTAs.
The free trade agreement that European Union is pushing India to sign could put an end to India's status as the pharmacy of the developing providing affordable medicines, especially HIV drugs to countries like Brazil, Thailand, South Africa, Zimbabwe and several others. The negotiations with EU are on at a feverish pace this week in Brussels even before the parliamentary standing committee looking into the free trade agreements (FTAs) has submitted its report.
The TPP negotiators are making decisions that will affect at least 600 million people, and potentially hundreds of millions more, in complete secrecy, and this is unacceptable.
Health Action International Europe, Oxfam and Action against AIDS Germany have serious concerns over the repercussions the EU-Thailand FTA will have on access to medicines in Thailand and the region.
As closed-door talks for the Trans-Pacific Partnership Agreement resume in Singapore this week, international medical humanitarian organization Médecins Sans Frontières calls on the US government to end its stall tactics and revise its proposals for what otherwise promises to be the most harmful trade deal ever for access to medicines in developing countries.
Days before leaders of the European Union arrived in Norway to collect this year’s Nobel Peace prize, Thai public health activists sent a letter to the northern powerhouse, warning that the EU’s 2012 accolades face a credibility test in this Southeast Asian country.
As free trade talks with the European Union reach the endgame, Ottawa is signalling it is prepared to give the Europeans at least part of what they asked for on drug patents — a move that could cost Canadians up to $900 million a year.
A concession on drug patents in a free trade deal with the European Union stands to cost Nova Scotians millions, Health and Wellness Minister David Wilson said Wednesday.
Civil society statement calling fpr rejection of the Conformity Assessment and Acceptance of Industrial Products protocol attached to the European Union-Israel Association Agreement
Although the EU is asking Canada to change its patent regime, it is not possible to do so just for the EU. The actual beneficiaries would be all of the world’s brand-name companies. Of the world’s top 12 health care companies by revenue only three or four are resident in the EU.
